On Monday, Esperion Therapeutics Inc (NASDAQ: ESPR) was -3.67% drop from the session before settling in for the closing price of $1.09. A 52-week range for ESPR has been $0.82 – $3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 44.77% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 84.04%. With a float of $194.67 million, this company’s outstanding shares have now reached $195.85 million.
In an organization with 304 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 79.35%, operating margin of 16.37%, and the pretax margin is -15.57%.
Esperion Therapeutics Inc (ESPR) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Esperion Therapeutics Inc stocks. The insider ownership of Esperion Therapeutics Inc is 1.76%, while institutional ownership is 58.70%. The most recent insider transaction that took place on Apr 17 ’25, was worth 106. In this transaction Chief Commercial Officer of this company sold 108 shares at a rate of $0.98, taking the stock ownership to the 370,218 shares. Before that another transaction happened on Apr 17 ’25, when Company’s Chief Financial Officer sold 8 for $0.96, making the entire transaction worth $8. This insider now owns 481,702 shares in total.
Esperion Therapeutics Inc (ESPR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 84.04% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
You can see what Esperion Therapeutics Inc (ESPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.21 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Let’s dig in a bit further. During the last 5-days, its volume was 4.4 million. That was inferior than the volume of 4.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 79.49%. Additionally, its Average True Range was 0.10.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 7.40%, which indicates a significant decrease from 79.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.43% in the past 14 days, which was higher than the 82.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3446, while its 200-day Moving Average is $1.9228. However, in the short run, Esperion Therapeutics Inc’s stock first resistance to watch stands at $1.0900. Second resistance stands at $1.1300. The third major resistance level sits at $1.1600. If the price goes on to break the first support level at $1.0200, it is likely to go to the next support level at $0.9900. Assuming the price breaks the second support level, the third support level stands at $0.9500.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
There are 198,149K outstanding shares of the company, which has a market capitalization of 208.06 million. As of now, sales total 332,310 K while income totals -51,750 K. Its latest quarter income was 69,110 K while its last quarter net income were -21,320 K.
